Resultados de procura - Robert A. Burger

Limitar resultados
  1. 1
    HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity

    HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity por Basmina Parmakhtiar, Robert A. Burger, Jai-Hyun Kim, John P. Fruehauf

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Prognostic factors in neuroendocrine small cell cervical carcinoma

    Prognostic factors in neuroendocrine small cell cervical carcinoma por John K. Chan, Vera Loizzi, Robert A. Burger, Joanne Rutgers, Bradley J. Monk

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

    Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study por Krishnansu S. Tewari, James Java, Ramez N. Eskander, Bradley J. Monk, Robert A. Burger

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

    Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study por Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, Joel I. Sorosky

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

    Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study por Bradley J. Monk, Michael W. Sill, Robert A. Burger, Heidi J. Gray, Thomas Buekers, Lynda D. Roman

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

    Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary perito... por Robert A. Burger, Mark F. Brady, Joon Haeng Rhee, Mika A. Sovak, George Kong, Hoa Nguyen, Michael A. Bookman

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Human Papillomavirus Type 18: Association With Poor Prognosis in Early Stage Cervical Cancer

    Human Papillomavirus Type 18: Association With Poor Prognosis in Early Stage Cervical Cancer por Robert A. Burger, Bradley J. Monk, Tom Kurosaki, Hoda Anton‐Culver, Steven A. Vasilev, Michael L. Berman, Sharon P. Wilczynski

    Publicado 1996
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    Incidence of Venous Thromboembolism by Type of Gynecologic Malignancy and Surgical Modality in the National Surgical Quality Improvement Program

    Incidence of Venous Thromboembolism by Type of Gynecologic Malignancy and Surgical Modality in the National Surgical Quality Improvement Program por Ashley Graul, Nawar Latif, Xiaochen Zhang, Lorraine T. Dean, Mark A. Morgan, Robert Giuntoli, Robert A. Burger, Sarah Kim, Emily Ko

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

    Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer por John Welsh, Patrick P. Zarrinkar, Lisa M. Sapinoso, S Kern, Cynthia Behling, Bradley J. Monk, David J. Lockhart, Robert A. Burger, Garret M. Hampton

    Publicado 2001
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer por Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Q. Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses por Carlos Bais, Barbara M. Mueller, Mark F. Brady, Robert S. Mannel, Robert A. Burger, Wei Wei, Koen M. Marien, Mark Kockx, Amreen Husain, Michael J. Birrer

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

    Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study por Leslie M. Randall, Bradley J. Monk, Kathleen M. Darcy, Chunqiao Tian, Robert A. Burger, Shu‐Yuan Liao, William A. Peters, Richard J. Stock, John P. Fruehauf

    Publicado 2008
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Maintenance Treatment with Bevacizumab Prolongs Survival in an<i>In vivo</i>Ovarian Cancer Model

    Maintenance Treatment with Bevacizumab Prolongs Survival in an<i>In vivo</i>Ovarian Cancer Model por Seiji Mabuchi, Yoshito Terai, Kenichiro Morishige, Akiko Tanabe-Kimura, Hiroshi Sasaki, Masanori Kanemura, Satoshi Tsunetoh, Yoshimichi Tanaka, Masahiro Sakata, Robert A. Burger, Tadashi Kimura, Masahide Ohmichi

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study por Gini F. Fleming, Virginia L. Brunetto, David Cella, Katherine Y. Look, Gary C. Reid, Adnan Munkarah, Richard Kline, Robert A. Burger, Annekathryn Goodman, R. Tucker Burks

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study

    Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study por Bradley J. Monk, Helen Q. Huang, Robert A. Burger, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Lari Wenzel

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

    Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study por Shu‐Yuan Liao, Kathleen M. Darcy, Leslie M. Randall, Chunqiao Tian, Bradley J. Monk, Robert A. Burger, John P. Fruehauf, William A. Peters, Richard J. Stock, Eric J. Stanbridge

    Publicado 2009
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

    Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer por Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey A. Douglas, Robert A. Burger, Deborah K. Armstrong, Robert M. Wenham, William P. McGuire

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

    Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study por J. Stuart Ferriss, James Java, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Joan L. Walker, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Robert A. Burger

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

    Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer por Ernest Han, Robert A. Burger, Kathleen M. Darcy, Michael W. Sill, Leslie M. Randall, Dana M. Chase, Basmina Parmakhtiar, Bradley J. Monk, Benjamin E. Greer, Patrick J. Connelly, Koen DeGeest, John P. Fruehauf

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary

    Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary por Seiji Mabuchi, Chiaki Kawase, Deborah A. Altomare, Ken‐ichirou Morishige, Masami Hayashi, Kenjiro Sawada, Kimihiko Ito, Yoshito Terai, Yukihiro Nishio, Andres J. Klein–Szanto, Robert A. Burger, Masahide Ohmichi, Joseph R. Testa, Tadashi Kimura

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: